At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Post-Mkt 05-15 18:58:45 EDT
326.31
-7.40
-2.22%
盘后326.57
+0.26+0.08%
18:08 EDT
High336.23Low325.16Vol3.45M
Open336.23D1 Closing333.71Amplitude3.32%
Mkt Cap175.71BTradable Cap175.23BTotal Shares538.48M
T/O1.13BT/O Rate0.64%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

20 People in Japan Died After Taking Amgen Drug -- WSJ
Dow Jones  ·  03:37
20 People in Japan Died After Taking Amgen Drug -- WSJ
ADVISORY-Incorrectly tagged Kissei alert withdrawn
Reuters  ·  05:16
ADVISORY-Incorrectly tagged Kissei alert withdrawn
Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports
Reuters  ·  04:13
Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports
Kissei Pharmaceutical: Initiating Info Dissemination to Encourage Careful Administration of Tavneos
THOMSON REUTERS  ·  04:11
Kissei Pharmaceutical: Initiating Info Dissemination to Encourage Careful Administration of Tavneos
BRIEF-20 People In Japan Who Took Amgen's Tavneos Have Died, And At Least 22 Developed A Potentially Fatal Liver Injury, As Per Kissei Pharmaceutical- WSJ
Reuters  ·  04:01
BRIEF-20 People In Japan Who Took Amgen's Tavneos Have Died, And At Least 22 Developed A Potentially Fatal Liver Injury, As Per Kissei Pharmaceutical- WSJ
Kissei Told Doctors Friday to Stop Prescribing Amgen's Tavneos Drug to New Patients - WSJ
THOMSON REUTERS  ·  04:00
Kissei Told Doctors Friday to Stop Prescribing Amgen's Tavneos Drug to New Patients - WSJ
Dow's 381-Point Drop Led By Losses In Caterpillar, NVIDIA Corp. Shares
Dow Jones  ·  01:25
Dow's 381-Point Drop Led By Losses In Caterpillar, NVIDIA Corp. Shares
Sino Biopharmaceutical Stock Slides 3.6% in Hong Kong, Underperforms Competitors
Dow Jones  ·  05-15 16:31
Sino Biopharmaceutical Stock Slides 3.6% in Hong Kong, Underperforms Competitors
Amgen Is Maintained at Overweight by Piper Sandler
Dow Jones  ·  05-14 23:32
Amgen Is Maintained at Overweight by Piper Sandler
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Reuters  ·  05-14 15:24
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Daiwa Securities Adjusts Price Target on Amgen to $390 From $410, Maintains Outperform Rating
MT Newswires Live  ·  05-13 19:53
Daiwa Securities Adjusts Price Target on Amgen to $390 From $410, Maintains Outperform Rating
Amgen Inc. Stock Outperforms Competitors On Strong Trading Day
Dow Jones  ·  05-13
Amgen Inc. Stock Outperforms Competitors On Strong Trading Day
Sino Biopharmaceutical Stock Rises 2.1% in Hong Kong, Outperforms Competitors
Dow Jones  ·  05-12
Sino Biopharmaceutical Stock Rises 2.1% in Hong Kong, Outperforms Competitors
Amgen advances MariTide obesity drug into Phase 3 MARITIME program
Reuters  ·  05-12
Amgen advances MariTide obesity drug into Phase 3 MARITIME program
Sino Biopharmaceutical Stock Climbs 4.2% in Hong Kong, Outperforms Competitors
Dow Jones  ·  05-11
Sino Biopharmaceutical Stock Climbs 4.2% in Hong Kong, Outperforms Competitors
EXCLUSIVE-Kennedy's health officials explored US ban of some widely used antidepressants, sources say
Reuters  ·  05-09
EXCLUSIVE-Kennedy's health officials explored US ban of some widely used antidepressants, sources say
Amgen Halts Phase 2 HZN-1116 Trial in Sjögren’s: What Investors Should Know
TIPRANKS  ·  05-09
Amgen Halts Phase 2 HZN-1116 Trial in Sjögren’s: What Investors Should Know
CytomX Q1 revenue falls but beats analyst expectations
Reuters  ·  05-08
CytomX Q1 revenue falls but beats analyst expectations
Amgen CFO, R&D chief present at BofA Merrill Lynch Global Healthcare Conference webcast
Reuters  ·  05-08
Amgen CFO, R&D chief present at BofA Merrill Lynch Global Healthcare Conference webcast
Amgen upgraded to Buy from Hold at Freedom Broker
TIPRANKS  ·  05-07
Amgen upgraded to Buy from Hold at Freedom Broker

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--